Literature DB >> 8490757

Immunotherapy of renal cell carcinoma.

G P Haas1, G G Hillman, B G Redman, J E Pontes.   

Abstract

Immunologic approaches to the therapy of metastatic renal cell carcinoma have provided moderate improvement in response rates for a disease that is extremely resistant to all forms of treatment. This article reviews recent clinical efforts using immunotherapy for renal cell carcinoma, including the adoptive transfer of cytotoxic killer cells and/or the use of biologic response modifiers, such as interferon and interleukin-2.

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8490757     DOI： 10.3322/canjclin.43.3.177

Source DB:  PubMed          Journal:  CA Cancer J Clin        ISSN： 0007-9235            Impact factor:   508.702


  5 in total

Review 1.  Treatment of metastatic renal cell carcinoma.

Authors:  Maxine Sun; Giovanni Lughezzani; Paul Perrotte; Pierre I Karakiewicz
Journal:  Nat Rev Urol       Date:  2010-05-11       Impact factor: 14.432

2.  L- and M2-pyruvate kinase expression in renal cell carcinomas and their metastases.

Authors:  U Brinck; E Eigenbrodt; M Oehmke; S Mazurek; G Fischer
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

3.  Growth and major histocompatibility antigen expression regulation by IL-4, interferon-gamma (IFN-gamma) and tumour necrosis factor-alpha (TNF-alpha) on human renal cell carcinoma.

Authors:  G G Hillman; R K Puri; M A Kukuruga; J E Pontes; G P Haas
Journal:  Clin Exp Immunol       Date:  1994-06       Impact factor: 4.330

4.  In vivo assessment of the antiproliferative properties of interferon-alpha during immunotherapy: Ki-67 (MIB-1) in patients with metastatic renal cell carcinoma.

Authors:  F Donskov; N Marcussen; M Hokland; R Fisker; H H T Madsen; H von der Maase
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

5.  Two randomised phase II trials of subcutaneous interleukin-2 and histamine dihydrochloride in patients with metastatic renal cell carcinoma.

Authors:  F Donskov; M Middleton; K Fode; P Meldgaard; W Mansoor; J Lawrance; N Thatcher; H Nellemann; H von der Maase
Journal:  Br J Cancer       Date:  2005-10-03       Impact factor: 7.640
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.